The ID3 Knockout NCI-H1299 Polyclonal Cells are a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the ID3 gene in the NCI-H1299 human non-small cell lung carcinoma line. This heterogeneous polyclonal pool avoids clonal selection biases and provides a robust loss-of-function model for studying ID3 in lung adenocarcinoma. CRISPR/Cas9 editing ensures efficient target-gene knockout, enabling researchers to examine ID3??s role as a dominant-negative inhibitor of bHLH transcription factors.
NCI-H1299 is a lung adenocarcinoma line derived from lymph node metastasis, characterized by a TP53-null background with wild-type KRAS and EGFR. This p53-deficient genetic context is ideal for exploring p53-independent tumorigenic mechanisms and therapeutic sensitivities. Its metastatic origin also makes it relevant for invasion and migration studies. Thus, NCI-H1299 serves as a physiologically appropriate host for evaluating ID3 loss in aggressive p53-null lung cancer.
ID3 acts as a dominant-negative inhibitor of bHLH transcription factors, including E2A (TCF3/E12/E47), HEB, and MyoD, thereby repressing differentiation and promoting proliferation and survival. Its expression is regulated by BMP (via BMPR2 and SMAD1/5/8), TGF-?? (via SMAD2/3), EGF, FGF, hypoxia, Notch, Wnt/??-catenin/TCF, and STAT3. Downstream, ID3 modulates p21/CDKN1A, p57/CDKN1C, Cyclin D1, c-MYC, Bcl-2, and VEGFA. The knockout abolishes ID3-mediated inhibition of bHLH factors, leading to derepression of antiproliferative and proapoptotic genes.
In NCI-H1299 cells, ID3 knockout creates a valuable model for studying p53-independent growth control through bHLH transcription factor activation. Disruption of ID3 may sensitize cells to apoptosis via p21 and p57 upregulation, reducing Cyclin D1 and c-MYC levels. With wild-type KRAS and EGFR, this system permits focused interrogation of BMP/SMAD and TGF-?? pathways, avoiding confounding effects from these oncogenic drivers, and facilitates research into metastasis, stemness, and drug resistance in TP53-null lung adenocarcinoma.
These polyclonal knockout cells are applicable in cancer biology and signal transduction studies, supporting assays such as Western blotting, RT-qPCR, proliferation, colony formation, apoptosis, cell cycle, and migration/invasion analyses. They are suited for drug screening targeting BMP/TGF-?? signaling, differentiation therapy, and bHLH gene regulation research. This loss-of-function model enables dissection of ID3-dependent networks in tumorigenesis. For further information, contact Ascent Research.
